Ranolazine for the treatment of refractory angina in a veterans population
Introduction
Pivotal ranolazine trials did not include patients with refractory angina on optimal antianginal medications. The purpose of this study was to evaluate the efficacy and safety of ranolazine for the treatment of angina refractory to maximal medical treatment in a veterans population.
Hypothesis
We hypothesized that ranolazine would decrease the number of weekly self-reported angina episodes and sublingual nitroglycerin tablet utilization as compared to baseline.
Hypothesis
We hypothesized that ranolazine would decrease the number of weekly self-reported angina episodes and sublingual nitroglycerin tablet utilization as compared to baseline.
Methods
The study was a retrospective cohort of patients experiencing three or more angina episodes per week despite treatment with maximally tolerated antianginal therapy (beta-blockers, long-acting dihydropyridine calcium channel blockers and long-acting nitrates). We assessed change in the number of self-reported weekly angina episodes and of sublingual nitroglycerin utilization. Change in the QTc interval was evaluated as a safety endpoint. All comparisons were made from baseline to endpoint using a Wilcoxon signed rank test for paired data.
Only gold members can continue reading. Log In or Register to continue
